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Abstract. Human non-small cell lung cancer (NSCLC) is 
associated with an extremely poor prognosis especially for the 
40% of patients who develop brain metastasis, and few treat-
ment strategies exist. Cucurbitacin E (CuE), an oxygenated 
tetracyclic triterpenoid isolated from plants particularly of 
the family Cucurbitaceae, has shown anti-tumorigenic prop-
erties in several types of cancer, yet the mechanism remains 
unclear. Yes-associated protein (YAP), a main mediator of 
the Hippo signaling pathway, promotes tumorigenesis, drug 
resistance and metastasis in human NSCLC. The present 
study was designed to ascertain whether CuE inhibits YAP 
and its downstream gene expression in the human NSCLC 
cell lines H2030-BrM3 (K-rasG12C mutation) and PC9-BrM3 
(EGFRΔexon19 mutation), which have high potential for brain 
metastasis. The efficacy of CuE in suppressing brain metastasis 
of H2030-BrM3 cells in a murine model was also investigated. 
It was found that after CuE treatment in H2030-BrM3 and 
PC9-BrM3 cells, YAP protein expression was decreased, 
and YAP signaling GTIIC reporter activity and expression of 
the downstream genes CTGF and CYR61 were significantly 
(P<0.01) decreased. CuE treatment also reduced the migration 
and invasion abilities of the H2030-BrM3 and PC9-BrM3 
cells. Finally, our in vivo study showed that CuE treatment 
(0.2 mg/kg) suppressed H2030-BrM3 cell brain metastasis 
and that mice treated with CuE survived longer than the 
control mice treated with 10% DMSO (P=0.02). The present 
study is the first to demonstrate that CuE treatment inhibits 
YAP and the signaling downstream gene expression in human 
NSCLC in vitro, and suppresses brain metastasis of NSCLC in 
a murine model. More studies to verify the promising efficacy 
of CuE in inhibiting brain metastasis of NSCLC and various 
other cancers may be warranted.
Introduction
Brain metastasis affects approximately 40% of patients with 
non-small cell lung cancer (NSCLC) (1,2). The prognosis for 
these patients is extremely poor; median survival is less than 
three months without treatment (3,4). Treatment options for 
those patients whose tumors lack targetable mutations remain 
quite limited. For example, erlotinib, an epidermal growth 
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is an 
effective target therapy for brain metastatic lung adenocarci-
noma harboring EGFR exon 19 deletion or exon 21 L858R 
mutations (5-8). Anaplastic lymphoma kinase (ALK) inhibi-
tors including ceritinib and alectinib have better response 
rates than conventional chemotherapy for brain metastatic 
NSCLC patients with ALK-rearrangement mutation (9,10). 
Although the K-ras mutation is common in NSCLC patients 
(15-30%), there is still no approved target therapy drug for 
K-ras mutant metastatic NSCLC (11,12). There is therefore 
an important need to develop novel drugs for the treatment 
of brain metastatic NSCLC patients without targetable driven 
mutations.
Cucurbitacin E (CuE, a-elaterin) (Fig. 1A) is a tetracyclic 
triterpene and a biochemical natural compound from the 
family of cucurbitacins. CuE can be isolated from natural 
plants such as those of the family Cucurbitaceae (gourd, 
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cucumber, pumpkins) (13). Previous studies have shown that 
CuE inhibits the proliferation, invasion and migration abilities 
of various types of cancers, including lung, colorectal and 
breast, yet the mechanism by which it performs these functions 
and the signaling pathway remain unclear (13-19).
Yes-associated protein (YAP) is a key mediator protein in 
the Hippo (also known as the Salvador-Warts-Hippo) signaling 
pathway, and is reportedly an important oncogenic protein in 
various types of cancer (20,21). Recently, YAP was found to 
promote tumorigenesis, invasion, drug resistance, brain metas-
tasis and immune evasion in human NSCLC (22-28). Thus, YAP 
has been suggested as a therapeutic target for metastatic NSCLC. 
However, to date, no molecular inhibitor targeting YAP has been 
developed for the treatment of NSCLC. Therefore, identification 
of a natural biochemical compound that can inhibit the YAP 
signaling pathway is an alternative strategy.
In the present study, we sought to determine whether CuE 
inhibits YAP expression in the NSCLC cell lines H2030-BrM3 
(K-rasG12C mutation) and PC9-BrM3 (EGFRΔexon19 mutation), 
which have high potential for brain metastasis. We also 
investigated the efficacy of CuE in suppressing human NSCLC 
brain metastasis in a murine model.
Materials and methods
Cell culture. Human metastatic NSCLC cell lines H2030-BrM3 
(K-rasG12C mutation) (P9) and PC9-BrM3 (EGFRΔexon19 
mutation) (P40) were gifts from Professor Joan Massagué 
(Metastasis Research Center, Memorial Sloan Kettering 
Cancer Center, New York, NY, USA). The H2030-BrM3 and 
PC9-BrM3 cell lines are in vivo selection of metastatic deriva-
tives from NCI-H2030 (K-rasG12C mutation) and PC9 cell lines 
(EGFRΔexon19 mutation). The two cell lines were derived 
and authenticated by left ventricle inoculation as previously 
described (29,30). Cells were maintained in RPMI-1640 
medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and streptomycin (100 mg/ml) (UCSF Cell 
Culture Facility, San Francisco, CA, USA), and cultured at 
37˚C in a humid incubator with 5% CO2.
Animal studies. All animal studies strictly followed UCSF 
institutional guidelines (Institutional Animal Care and Use 
Committee approval no. AN103205-03). Twenty athymic nude 
(CrTac:NCr-Foxn1nu) female mice, 6-8 weeks of age (body 
weight at ~20 g) were purchased from Taconic Farms, Inc. 
(Hudson, NY, USA) and maintained in ventilated cages (with 
reach food and water) at a constant temperature (20‑22˚C) and 
a 12 h light dark cycle in UCSF's Laboratory Animal Resource 
Center (LARC) facility. The murine experiments were initi-
ated when mice were older than 10 weeks. A metastatic 
murine model was created by injecting 500,000 H2030-BrM3 
cells suspended in 100 µl of PBS into the left ventricle via a 
percutaneous approach as previously described (29,30). To test 
whether cucurbitacin E (CuE) (Sigma Aldrich; Merck KGaA) 
could control NSCLC cell line H2030-BrM3 metastasis in our 
murine model, mice were divided into two groups of n=10 
each. The control group was administered an intraperito-
neal (i.p.) injection of 10% dimethyl sulfoxide (DMSO), and 
the treatment group was administered an i.p. injection of 
0.2 mg/kg of CuE. Both treatments began on the day following 
cell injection and were administered every other day. The mice 
were euthanized when they showed symptoms of paralysis, 
appeared extremely sick or a tumor size exceeding 2 cm3, 
according to the guidelines established by the UCSF LARC 
and tumor tissues were collected. Survival was assessed from 
the day of cell injection to the day mice were euthanized.
To monitor the condition of brain metastasis in the mice, 
bioluminescent imaging (Caliper Life Sciences, Waltham, 
MA, USA) was used. For this, mice were injected with 
D-luciferin potassium salt (SYD Labs, Inc., Natick, MA, USA) 
at a dose of 150 mg/kg i.p., anesthetized by inhalant isoflurane 
1-5% in oxygen, and then placed into the Xenogen IVIS® 
spectrum imaging system (PerkinElmer, Boston, MA, USA) 
at 10 min after D-luciferin potassium salt injection. Images 
were recorded with an exposure time of 1 min.
Cell viability assay. H2030-BrM3 and PC9-BrM3 cells were 
cultured in a 96-well plate and treated with different doses 
of CuE (Sigma Aldrich; Merck KGaA) (0, 0.01, 0.03, 0.1, 0.3, 
1, 3, 10, 30 and 100 µM). After 72 h of incubation, the cells 
were lysed and CellTiter-Glo Luminescent Cell Viability 
Assay reagent (Promega) was added to generate luminescent 
signaling. Luminescent signaling was detected by using the 
GloMax-96 Microplate Luminometer (Promega, Madison, 
WI, USA). GraphPad Prism 5.0 software (GraphPad Software, 
Inc., La Jolla, CA, USA) was used to analyze proportional 
cell viability and calculate dose-response curves and the half 
maximal inhibitory concentration (IC50) value.
Luciferase gene transfection. The pGreenFire1-CMV Virus 
(pTRH1 CMV dscGFP T2A Fluc) positive control was 
purchased from System Bioscience LLC (Palo Alto, CA, 
USA). Virus particles were mixed with transfection reagents 
and medium according to the manufacturer's protocol, and 
added to the H2030-BrM3 cells cultured in 12-well plates. 
Fluorescence microscopy was used to determine the efficacy 
of transfection at 48 h after transfection.
Western blot analysis. The samples were run on 4-20% 
gradient SDS-polyacrylamide gels (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) and then were transferred to Immobilon-P 
nitrocellulose membranes (Millipore, Bellerica, MA, USA). 
The membranes were probed with the following primary 
antibodies: Rabbit anti-YAP (Cell Signaling, cat. no. 4912; 
dilution 1:1,000), anti-ERK1/2 (Cell Signaling, cat. no. 4912; 
dilution 1:1,000) and mouse anti-GAPDH (Sigma-Aldrich; 
Merck KGaA; cat. no. 100242-MM05; dilution 1:10,000) 
at 4˚C overnight after blocking with 5% non‑fat milk. The 
membranes were then incubated with species‑specific conju-
gated secondary antibodies (GE Dharmacon) (cat. no. NA934, 
anti-rabbit for YAP; cat. no. NA931, anti-mouse for GAPDH) 
at room temperature for 1 h. Finally, an ECL blotting analysis 
system (Amersham Pharmacia Biotech, Piscataway, NJ, USA) 
was used to detect protein expression.
Protein degradation assay. H2030-BrM3 and PC9-BrM3 cells 
were placed in 6-well plates, and treated with either 0.1 µM 
CuE or DMSO (control). After 24 h of treatment, the cells were 
treated with 100 µg/ml cycloheximide (CHX) (Sigma-Aldrich; 
Merck KGaA), an inhibitor of protein synthesis. Cells were 
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harvested at the time points of 0, 1 and 2 h after CHX treat-
ment. Total proteins were extracted and YAP expression was 
analyzed by western blot analysis.
Luciferase reporter assay. The cell lines H2030-BrM3 and 
PC9-BrM3 were placed in 24-well plates and transfected with 
8xGTIIC-luciferase plasmid (Addgene, Cambridge, MA, USA) 
and Renilla luciferase pRL-TK plasmid (Promega, Madison, 
WI, USA) by using transfection reagent Lipofectamine 2000 
(Invitrogen; Thermo Fisher Scientific, Inc.). At 24 h after 
transfection, the cells were treated with CuE. After a 24 h 
treatment, the cells were lysed and luciferase activity was 
assayed by using Dual-Luciferase Reporter Assay system 
(Promega). Luminescent signaling was detected by using 
GloMax-96 Microplate Luminometer. All luciferase activi-
ties were normalized to Renilla activity. All experiments of 
luciferase reporter assay were triplicated to achieve statistical 
significance [DMSO (n=3), CuE 0.05 µM (n=3), CuE 0.1 µM 
(n=3)].
RNA isolation, cDNA synthesis, and quantitative real‑time 
RT‑PCR. Total RNA was extracted from cells by using the 
High Pure RNA Isolation Kit (Roche, Indianapolis, IN, USA). 
The iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.) 
was used to transcribe RNA to cDNA, and the cDNA was used 
as the template for real-time PCR. Commercially available 
primers and probe sequences (Applied Biosystems; Thermo 
Fisher Scientific, Inc.) were used to detect YAP, CYR61, CTGF, 
EREG and endogenous control gene β-glucuronidase (GUSB) 
gene expression. Applied Biosystems Relative Quantification 
software (Version C; Thermo Fisher Scientific, Inc.) was used 
for mRNA expression analysis. Real-time PCR detection 
was conducted using TaqMan Technology on an Applied 
Biosystems 7000 sequence detection system (Thermo Fisher 
Scientific, Inc.). All experiments of real‑time RT‑PCR were 
triplicated to achieve statistical significance [DMSO (n=3), 
CuE 0.05 µM (n=3), CuE 0.1 µM (n=3)].
Wound‑healing and Transwell invasion assay. For the 
wound-healing migration assay, H2030-BrM3 and PC9-BrM3 
cells were subcultured in 6-well plates until the condition of 
confluence was reached. The plates were scratched using a 
200 µl pipette tip, and the cells were grown continuously. In 
a test of CuE treatment, 0.05 µM was added after the scratch. 
Phase contrast images were captured at the time of the scratch 
(0 h) and 18 h later with a Primo Vert microscope (magnifica-
tion x100, x200 and x400, respectively; Carl Zeiss, Gottingen, 
Germany), and the distance of cell movement was measured 
by ImageJ software (National Institutes of Health, Bethesda, 
MD, USA).
The 6-well plate Transwell system used for the Transwell 
invasion assay was purchased from Corning Inc. (Corning, NY, 
USA). The upper chamber of the Transwell plate was coated 
with 300 µl mMatrigel. Next, H2030-BrM3 and PC9-BrM3 
cells were trypsinized and re-suspended in serum-free medium 
and the cells were seeded on the upper chamber of the Transwell 
plate. CuE (0.05 µM) was added with serum-free medium to 
the upper chamber. The lower chamber was infused with 2 ml 
complete growth medium (10% FBS). The gel in the upper 
chamber of the Transwell plate was wiped after incubation 
at 37˚C for 48 h. The membrane of the upper chamber was 
stained by crystal violet for 10 min after methanol fixation. 
The Primo Vert microscope was again used to observe the 
cells on the lower side of the membrane, and phase contrast 
images were captured at x100, x200 and x400 magnification.
Wound-healing and Tanswell invasion assays were trip-
licated to achieve statistical significance [DMSO (n=3, CuE 
0.05 µM (n=3)].
Histologic analysis and immunohistochemistry. After mice 
were euthanized, the tumor tissues from brain metastases 
were harvested, immediately fixed in 10% paraformaldehyde 
for 24 h and then embedded in paraffin. Histological sections 
of the tissues were stained with hematoxylin and eosin (H&E) 
stain for general morphological analysis. The morphological 
analysis to verify brain metastasis in the stained tissues was 
performed by an experienced pathologist. The YAP immuno-
histochemistry (IHC) staining was conducted as previously 
described (27). All images were obtained using a Zeiss 
Axioscop 2 microscope at x100, x200 and x400 magnification 
(Carl Zeiss Inc.).
Statistical analysis. All statistical analyses were conducted 
using GraphPad Prism (version 5.0; GraphPad Software, 
San Diego, CA, USA). Data are expressed as mean ± standard 
deviation (SD) from three independent experiments. t-tests 
were used to compare the differences between two groups, 
and one-way ANOVA followed by Turkey multiple compari-
sons was used to compare differences among >2 groups. A 
Kaplan-Meier survival curve was calculated to determine 
survival in the animal experiments. The experiments of 
reporter assay, real-time RT-PCR, wound-healing and 
Transwell invasion assays were triplicated to achieve statistical 
significance. All P‑values were 2‑sided and considered to be 
statistically significant at P<0.05 (*P<0.05, **P<0.01, ***P<0.001 
as indicated in the figures and legends).
Results
CuE decreases YAP protein expression in H2030‑BrM3 and 
PC9‑BrM3 cells. The cell viability assay of H2030-BrM3 
and PC9-BrM3 cells treated with CuE yielded IC50 values of 
0.146 and 0.187 µM, respectively (Fig. 1B and C). Western 
blotting showed that the level of YAP protein was decreased 
after treatment with 0.05 and 0.1 µM CuE in the H2030-BrM3 
and PC9-BrM3 cells when compared to the DMSO control 
(Fig. 1D). The YAP protein degradation assay showed that in 
H2030-BrM3 and PC9-BrM3 cells treated with 0.1 µM CuE, 
YAP protein expression reached low levels at 2 h when compared 
to the DMSO-treated controls (Fig. 1E). Real-time PCR showed 
that YAP mRNA expression was significantly decreased in the 
H2030-BrM3 and PC9-BrM3 cell lines after treatment with 
0.05 (P<0.001 and P<0.01) and 0.1 µM CuE (both P<0.001) 
when compared with the DMSO control (Fig. S1A and B). 
Western blot analysis showed that ERK1/2 protein was signifi-
cantly decreased after treatment with 0.05 and 0.1 µM CuE in 
the H2030-BrM3 and PC9-BrM3 cell lines (Fig. S1C and D).
CuE decreases GTIIC reporter activity and YAP downstream 
gene mRNA expression. After verifying that CuE decreases 
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Figure 1. CuE decreases YAP protein in H2030-BrM3 and PC9-BrM3 cell lines. (A) Chemical structure of CuE. Cell viability analysis in (B) H2030-BrM3 
and (C) PC9-BrM3 cells after CuE treatment. (D) YAP protein level was decreased in H2030-BrM3 and PC9-BrM3 cell lines after 0.05 and 0.1 µM CuE 
treatment when compared to the DMSO control. (E) YAP protein degradation assay showed that YAP protein was degraded more rapidly after 0.1 µM CuE 
treatment when compared with the DMSO control. CuE, cucurbitacin E; IC50, half maximal inhibitory concentration; CHX, cycloheximide; DMSO, dimethyl 
sulfoxide; YAP, Yes-associated protein.
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YAP protein expression in H2030-BrM3 and PC9-BrM3 cells, 
we ascertained whether it could also decrease GTIIC reporter 
activity and YAP downstream gene mRNA expression. We 
demonstrated that GTIIC reporter activity in the H2030-BrM3 
and PC9‑BrM3 cell lines was significantly decreased after 
0.05 and 0.1 µM CuE treatment compared to the DMSO 
control (all P<0.001) (Fig. 2A and B). In both cell lines, mRNA 
expression of the YAP downstream genes CTGF and CYR61 
was significantly decreased after 0.05 and 0.1 µM CuE treat-
ment (P<0.01) (Fig. 2C and D), as was mRNA expression of 
epidermal growth factor (EGF), epiregulin (EREG) (P<0.05) 
(Fig. S1E and F).
CuE reduces migration and invasion abilities of H2030‑BrM3 
and PC9‑BrM3 cells. To investigate whether CuE could 
reduce the migration and invasion abilities of H2030-BrM3 
and PC9-BrM3 cells, we used wound closure and Transwell 
invasion assays. The migration assay showed that the wound 
closure rate was significantly decreased in the H2030‑BrM3 
and PC9-BrM3 cells after 0.05 µM CuE treatment (P<0.01 
and P<0.001) when compared with the DMSO control 
(Fig. 3A-D). The Transwell invasion assay showed that the 
number of cells that invaded the lower side of the membrane 
was significantly decreased in both cell lines after 0.05 µM 
CuE treatment (P<0.01) when compared to the DMSO control 
(Fig. 3E-H) (Fig. S2).
CuE decreases the burden of brain metastasis in an in vivo 
H2030‑BrM3 cell murine model of brain metastasis. To 
test the efficacy of CuE in suppressing brain metastasis 
of H2030-BrM3 cells in vivo, mice were inoculated with 
H2030-BrM3 cells through percutaneous left ventricle 
injection and then treated with CuE at a dose of 0.2 mg/kg. 
Control mice were treated with 10% DMSO. Bioluminescent 
imaging showed that mice treated with CuE had significantly 
decreased brain metastatic burden compared to the control 
group at day 35 (week 7) (P=0.034 (Fig. 4A and B). Mice 
treated with CuE survived significantly longer than those 
treated with 10% DMSO (P=0.0212) (Fig. 4C).
CuE decreases nuclear YAP immunohistochemical (IHC) 
staining of mouse brain tumor tissue. After mice were 
euthanized, brain tissues were collected from the DMSO 
control and CuE-treated groups for histological analysis. 
H&E staining was assayed to verify that H2030-BrM3 tumor 
cell metastasis appeared in the mouse model. Metastasis 
of H2030-BrM3 tumor cells within brain tissues could be 
observed by H&E staining (Fig. 5A). To observe the late 
effect of CuE treatment on YAP in regards to brain metas-
tasis, nuclear YAP IHC staining was performed. The results 
showed that nuclear YAP IHC staining was decreased in 
the brain tissue of the CuE-treated group when compared 
to that observed in the brain tissue of the control DMSO 
group (Fig. 5B).
Discussion
Although the natural biochemical compound CuE has been 
shown to inhibit the proliferation, invasion and migration abili-
ties of various types of cancer, the mechanism and the signaling 
pathway remain unclear, until now. Our study revealed that 
CuE inhibited YAP protein expression in the NSCLC cell 
lines H2030-BrM3 and PC9-BrM3, which were derived 
from NSCLC cell lines NCI-H2030 (K-rasG12C mutation) and 
Figure 2. Hippo reporter activity and downstream gene expression are decreased after 0.05 and 0.1 µM CuE treatment in H2030-BrM3 and PC9-BrM3 cells. 
GTIIC reporter activity was significantly decreased after 0.05 and 0.1 µM CuE treatment in (A) H2030‑BrM3 and (B) PC9‑BrM3 cell lines. CTGF and CYR61 
mRNA expression was significantly decreased after either dose of CuE in the (C) H2030‑BrM3 and (D) PC9‑BrM3 cell lines. Error bars indicate standard 
deviations; **P<0.01, ***P<0.001 when compared to the DMSO control. CuE, cucurbitacin E; DMSO, dimethyl sulfoxide.
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Figure 3. Analysis of cell migration and invasion abilities of H2030-BrM3 and PC9-BrM3 cells after CuE treatment. Decrease in cell migration ability 
in the (A) H2030-BrM3 and (C) PC9-BrM3 cells after 0.05 µM CuE treatment. (B and D) Quantitative analysis of migration assay result, indicating CuE 
treatment significantly decreased cell migration ability. Decrease in cell invasion ability in the (E) H2030‑BrM3 and (G) PC9‑BrM3 cells after 0.05 µM CuE 
treatment. (F and H) Quantitative analysis of the Transwell invasion assay result, indicating that 0.05 µM CuE treatment decreased cell invasion ability in the 
H2030-BrM3 and PC9-BrM3 cells. Error bars indicate standard deviations; **P<0.01, ***P<0.001, when compared to the DMSO control. CuE, cucurbitacin E; 
DMSO, dimethyl sulfoxide.
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Figure 4. CuE treatment suppresses brain metastasis of H2030-BrM3 cells in a murine model (control 10% DMSO n=10, CuE treatment 0.2 mg/kg n=10). 
(A) Bioluminescence images of mice treated with CuE and DMSO. (B) Tumor metastasis burden in control mice and mice treated with CuE based on photon 
flux (photons per second) (P=0.007 at 5 weeks and P=0.034 at 7 weeks). (C) Kaplan‑Meier survival curves for control and CuE‑treated mice (P=0.0212). 
(D) Hypothetical model of our study. In H2030-BrM3 cells, activation of YAP increased the mRNA expression of downstream genes CTGF and CYR61, which 
form an autocrine loop to enhance the MAPK signaling pathway. This enhancement increased the invasion and migration abilities and the metastatic potential of 
H2030-BrM3 cells. CuE treatment inhibited YAP protein expression, and possibly also inhibited YAP at the transcriptional level. Therefore, CuE inhibited the 
brain metastasis of H2030-BrM3 cells by inhibiting the YAP signaling pathway. CuE, cucurbitacin E; DMSO, dimethyl sulfoxide; YAP, Yes-associated protein.
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PC9 (EGFRΔexon19 mutation), which show very strong brain 
metastatic potential in murine experiments (27,29). We veri-
fied that CuE decreases YAP GTIIC Hippo reporter activity, 
and expression of the downstream genes connective tissue 
growth factor (CTGF) and cysteine-rich angiogenic inducer 61 
(CYR61). Collectively, these results suggest that CuE inhibits 
tumorigenesis, invasion and migration thorough inhibition of 
the YAP signaling pathway.
Figure 5. Histological analysis of the mouse brain tissue (control 10% DMSO n=3, CuE treatment 0.2 mg/kg n=3). (A) H&E staining was performed to verify that 
brain metastasis of H2030-BrM3 cells appeared in the mouse model. Arrows point to the metastatic tumors in brain tissues from control mice and mice treated 
with CuE. (B) Nuclear YAP immunohistochemical (IHC) staining was conducted to observe the late effect of CuE treatment. The results showed that nuclear 
YAP IHC staining was decreased in the brain tissues of the CuE-treated group when compared to the tissues in the DMSO control group (arrows point to the 
nuclear YAP IHC staining). Scale bar, 100 µm. H&E, hematoxylin and eosin; CuE, cucurbitacin E; DMSO, dimethyl sulfoxide; YAP, Yes-associated protein.
ONCOLOGY REPORTS  42:  697-707,  2019 705
PC9-BrM3 cells contain an EGFRΔexon19 mutation and 
depend on the EGFR/mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) 
signaling pathway to maintain tumor survival. PC9-BrM3 
cells are sensitive to EGFR-tyrosine kinase inhibitor 
treatment (27,29,30). Although H2030-BrM3 cells have 
a K-rasG12C mutation, previous studies suggest that these 
cells do not fully depend on the EGFR/RAS/MAPK/ERK 
signaling pathway to maintain tumor survival (27,31). In 
addition, YAP has been suggested to be an oncogenic protein 
that partly takes over the K-ras mutation in H2030-BrM3 
cells (27,31). These findings may explain why YAP protein 
expression did not decrease equally after CuE treatment in 
the two cell lines.
Our experimental data showed that CuE treatment 
decreased YAP mRNA expression, ERK1/2 protein expres-
sion, and epidermal growth factor (EGF) EREG mRNA 
expression in H2030-BrM3 and PC9-BM3 cells. These results 
suggest that CuE inhibits YAP, at least in part, indirectly 
through the EGFR/MAPK/ERK signaling pathway. Previous 
studies have reported crosstalk between the Hippo/YAP and 
EGFR/MAPK/ERK signaling pathways in human NSCLC 
cells (22,24,32). Increased cytoplasmic YAP protein translo-
cates into the nucleus to form complexes with transcriptional 
enhancer factors (TEF; also known as TEAD) leading to 
activate transcription of downstream genes including CTGF, 
CYR61 and EGF such as EREG (22,24,27,32). Therefore, YAP 
regulates these downstream genes, including CTGF, CYR61 
and EREG, at the transcriptional mRNA level, not at the protein 
level. The increased expression of CTGF, CYR61 and EREG 
may form an autocrine loop with the EGFR/MAPK/ERK 
signaling pathway to re-enforce YAP protein expression. Two 
studies demonstrated that CuE inhibits the EGFR/MAPK/ERK 
signaling pathway in cancer cells (33,34). Recently, CuB was 
shown to inhibit the Hippo/YAP pathway in human colorectal 
cancer cell lines (35). These findings lead us to believe that 
CuE inhibits YAP indirectly through the EGFR/MAPK/ERK 
and Hippo/YAP signaling pathways in human NSCLC. 
Further studies in the future to investigate the effects of 
CuE on ErbB family receptors (EGFR, HER2, ErbB3 and 
HER4)/MAPK/ERK signaling pathway and Hippo kinase 
including neurofibromatosis 2 (NF2), large tumor suppressor 
homolog 1 (LATS1), LATS2, and mammalian sterile-20 like 
kinase 1 (MST1) in various cancers are suggested according 
to our findings. The dependence on the EGFR/MAPK/ERK 
signaling pathway of PC9-BrM3 cells may explain why more 
YAP protein was decreased and degraded after CuE treatment 
in that cell line when compared with that observed in the 
H2030-BrM3 cells.
Several studies have shown that CuE has anticancer 
activity to NSCLC by inhibiting oncogenic signaling path-
ways, including the Wnt signaling pathway and the Janus 
kinase (JAK)/signal transducer and activator of transcrip-
tion 3 (STAT3) signaling pathway (15,36,37). Wnt and STAT3 
signaling pathways were reportedly involved in regulating 
the expression of Hippo downstream genes CTGF and 
CYR61 (38‑41). Collectively, these findings may explain why 
the decrease of 50-80% in YAP protein by CuE treatment 
resulted in more than 90% of CTGF and CYR61 mRNA 
expression in H2030-BrM3 cells in our study.
According to several reports, YAP takes over KRAS as a 
cancer driver in KRAS-mutant NSCLC, and promotes cancer 
metastasis in NSCLC (41-45). A recent study found that K-ras 
mutant H2030-BrM3 cells have increased YAP protein and 
YAP downstream genes CTGF and CYR61 mRNA expres-
sions compared with parental H2030 cells (27). In that study, 
direct inhibition of YAP by short hairpin RNA suppressed 
brain metastasis of H2030-BrM3 cells in a mouse model. 
After verifying that CuE inhibits YAP signaling in vitro, we 
explored the efficacy of CuE in suppressing brain metastasis of 
H2030-BrM3 cells in a mouse model (Fig. 4D).
Our study is the first to show that CuE suppresses brain 
metastasis of human NSCLC in a murine model. A recent study 
showed that cucurbitacin B (another tetracyclic cucurbitane) 
inhibits the Hippo-YAP signaling pathway in colorectal cancer 
cells, but included no in vivo data (35). Another study demon-
strated that CuE inhibited breast cancer in a mouse model of 
metastasis by suppressing cell migration and invasion, but the 
anti-cancer mechanism of CuE was not investigated (18).
In conclusion, our study revealed that the anti-tumorigenic 
effects of CuE occur through inhibition of the YAP signaling 
pathway, and that CuE treatment suppressed brain metastasis of 
human NSCLC cells in a murine model. More studies to verify 
the promising efficacy of CuE in inhibiting brain metastasis of 
NSCLC and various other cancers may be warranted.
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